Article

Iceland-based Orf Genetics has raised $5 million in funding to enhance its mesokine growth factor portfolio, with an aim to reach $7 million as the round remains open. The company plans to significantly increase mesokine production to support cultivated meat producers transitioning to large-scale commercialization, projecting a fourteenfold capacity increase by 2027 and a ten-thousandfold by 2032. Utilizing bioengineered barley, Orf Genetics combines sustainable practices with 17 years of expertise in growth factor manufacturing.